Earnings Call Summary | Innate Pharma(IPHA.US) Q4 2023 Earnings Conference
Earnings Call Summary | Innate Pharma(IPHA.US) Q4 2023 Earnings Conference
The following is a summary of the Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript:
以下是Innate Pharma S.A.(IPHA)2023年第四季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Innate Pharma reported cash, cash equivalents, short-term investments and financial assets amounting to EUR 102.3 million at the end of 2023, and an additional EUR 15 million payment received from Sanofi in January 2024.
Revenue and other income from continuing operations totaled EUR 61.6 million in 2023, with operational expenses for the same period at EUR 74.3 million, 75% of which constitutes R&D expenses.
Innate Pharma報告稱,截至2023年底,現金、現金等價物、短期投資和金融資產總額爲1.023億歐元,2024年1月從賽諾菲又收到1500萬歐元的付款。
2023 年,來自持續經營業務的收入和其他收入總額爲 6,160 萬歐元,同期的運營支出爲 7,430 萬歐元,其中 75% 構成研發費用。
Business Progress:
業務進展:
Innate Pharma continues its late-stage developmental work with Lacutamab, targeting T cell lymphoma and is gathering data for mycosis fungoides.
Effort is being put into expanding the ANKET and Antibody Drug Conjugates (ADCs) portfolio, including licensed assets.
Innate's proprietary first in class NK cell engager platform now has differentiated ADC candidates, with their lead program, IPH45, targeting B-cell non-Hodgkin's lymphoma.
Sanofi has licensed 4 molecules from Innate, two of which are currently in the clinic.
Innate is exploring partnership opportunities for lacutamab's development for Cutaneous T-cell Lymphoma (CTCL).
Future plans include presentations at the ACR for ADC, OCD and IPH45 and project funding is secure till end of 2025.
Innate Pharma繼續與Lacutamab開展後期開發工作,靶向T細胞淋巴瘤,並正在收集類真菌病的數據。
正在努力擴大ANKET和抗體藥物偶聯物(ADC)產品組合,包括許可資產。
Innate首創的專有NK細胞參與者平台現已推出差異化ADC候選藥物,其主導項目 IPH45 針對B細胞非霍奇金淋巴瘤。
賽諾菲已從Innate獲得4種分子的許可,其中兩個目前已進入臨床階段。
Innate正在探索合作機會,爲lacutamab開發皮膚T細胞淋巴瘤(CTCL)。
未來的計劃包括在 ACR 上爲 ADC、OCD 和 IPH45 進行演講,項目資金將在 2025 年底之前得到保障。
More details: Innate Pharma IR
更多詳情: Innate Pharma
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。